Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04096716 · ClinicalTrials.gov registry record · Phase 1
Mapping Draining Lymph Nodes in CNS Malignancies
A Phase 1 study, sponsored by Washington University School of Medicine.
- Terminated
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT04096716 is a Phase 1 study that was terminated before completion, run by Washington University School of Medicine. The registered enrollment target is 14 participants.
The verdict
NCT04096716, a Phase 1 study, was terminated before completion, sponsored by Washington University School of Medicine.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
The purpose of this research study is to determine whether the lymph nodes that drain a brain tumor can be detected by imaging after injection of a substance called Tc-99m tilmanocept directly into the brain tissue around the tumor. Tc-99m tilmanocept is a radioactive substance that is used to find lymph nodes by injecting it and then scanning the body with a device that can trace its radioactivity. In this study, the investigators are looking to see how long it takes the Tc-99m tilmanocept to travel from the tumor to the lymph nodes. The investigators will be using it to map lymph nodes as they relate to specific brain areas.
Interventions
- DRUG Tc-99m tilmanocept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2019-12-03 |
| Est. Completion | 2022-04-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04096716
The ClinicalTrials.gov registry entry for NCT04096716 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tc-99m tilmanocept is the first listed.
NCT04096716 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04096716 about?
NCT04096716 is a clinical study titled "Mapping Draining Lymph Nodes in CNS Malignancies". The purpose of this research study is to determine whether the lymph nodes that drain a brain tumor can be detected by imaging after injection of a substance called Tc-99m tilmanocept directly into the brain tissue around the tumor. Tc-99m tilmanocept is a radioactive substance that is used to find ...
What is the current status of trial NCT04096716?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2019-12-03. Estimated completion is 2022-04-30.
What interventions are being tested in trial NCT04096716?
The interventions under investigation include: Tc-99m tilmanocept (DRUG).
Who is sponsoring clinical trial NCT04096716?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.